Alterations in homologous recombination repair genes in prostate

Interplay between androgen receptor (AR) and DNA damage repair in

Niraparib regimen improves outcomes for men with prostate cancer, HRR gene alterations

ESMO 2019: Central, Prospective Detection of Homologous Recombination Repair Gene Mutations in Tumor Tissue from >4000 Men with mCRPC Screened for the PROfound Study

Alterations in homologous recombination repair genes in prostate cancer brain metastases

ASCO 2022: Gene-by-Gene Analysis in the MAGNITUDE Study of Niraparib (NIRA) with Abiraterone Acetate and Prednisone (AAP) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Homologous Recombination Repair (HRR) Gene Alterations.

PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations

ASCO 2023: Presence of Somatic/Germline Homologous Recombination Repair Mutations and Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Receiving First‑line Treatment Stratified by BRCA Status

ESMO 2019: Central, Prospective Detection of Homologous Recombination Repair Gene Mutations in Tumor Tissue from >4000 Men with mCRPC Screened for the PROfound Study

Genomic correlates of clinical outcome in advanced prostate cancer

Precision Medicine for HRRm Testing in Prostate Cancer

The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies - Rimar - 2017 - Cancer - Wiley Online Library